Newron Pharmaceuticals S.p.A. (SWX:NWRN)
Switzerland · Delayed Price · Currency is CHF 9.06
+0.06 (0.67%)
Nov 12, 2026, 1:12 PM CET
Newron Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Newron Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of CHF 37.71. The average 1-year stock price forecast is 316.23% higher than the current stock price, while the lowest is CHF 18.79 (+107.40%) and the highest is CHF 71.66 (+690.95%).
Price Target: CHF 37.71 (+316.23%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Newron Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates CHF 26.00 → CHF 30.00 | Buy | Reiterates | CHF 26.00 → CHF 30.00 | +231.13% | Oct 22, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates CHF 19.00 | Buy | Reiterates | CHF 19.00 | +109.71% | Oct 4, 2026 |
Financial Forecast
Revenue This Year
8.32M
from 19.13M
Decreased by -56.49%
Revenue Next Year
57.90M
from 8.32M
Increased by 595.68%
EPS This Year
-1.58
from -0.66
EPS Next Year
0.59
from -1.58
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.